Impact of belief in neuroprotection on therapeutic intervention in Parkinson disease
Identifieur interne : 000151 ( Pmc/Checkpoint ); précédent : 000150; suivant : 000152Impact of belief in neuroprotection on therapeutic intervention in Parkinson disease
Auteurs : Rodger Elble ; Oksana Suchowersky ; Stephanie Shaftman ; William Weiner ; Peng Huang ; Barbara TilleySource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2010.
Abstract
We explored the hypotheses that an investigator’s belief in a putative neuroprotective agent might influence the timing of symptomatic intervention and the assessment of signs and symptoms of Parkinson patients with the Unified Parkinson Disease Rating Scale (UPDRS). These hypotheses were tested with Cox and general linear modeling, using data from a previously published double-blind placebo-controlled futility trial of coenzyme Q10 and GPI-1485. We found the investigators’ level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment.
Url:
DOI: 10.1002/mds.22997
PubMed: 20131372
PubMed Central: 2891220
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
PMC:2891220Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of belief in neuroprotection on therapeutic intervention in Parkinson disease</title><author><name sortKey="Elble, Rodger J" sort="Elble, Rodger J" uniqKey="Elble R" first="Rodger" last="Elble">Rodger Elble</name><affiliation><nlm:aff id="A1"> Department of Neurology, Southern Illinois University School of Medicine</nlm:aff><wicri:noCountry code="subfield">Southern Illinois University School of Medicine</wicri:noCountry></affiliation></author><author><name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name><affiliation><nlm:aff id="A2"> Departments of Medical Genetics and Clinical Neurosciences, University of Calgary</nlm:aff><wicri:noCountry code="subfield">University of Calgary</wicri:noCountry></affiliation></author><author><name sortKey="Shaftman, Stephanie" sort="Shaftman, Stephanie" uniqKey="Shaftman S" first="Stephanie" last="Shaftman">Stephanie Shaftman</name><affiliation><nlm:aff id="A3"> Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina</nlm:aff><wicri:noCountry code="subfield">Medical University of South Carolina</wicri:noCountry></affiliation></author><author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William" last="Weiner">William Weiner</name><affiliation><nlm:aff id="A4"> Department of Neurology, University of Maryland School of Medicine</nlm:aff><wicri:noCountry code="subfield">University of Maryland School of Medicine</wicri:noCountry></affiliation></author><author><name sortKey="Huang, Peng" sort="Huang, Peng" uniqKey="Huang P" first="Peng" last="Huang">Peng Huang</name><affiliation><nlm:aff id="A5"> Department of Oncology, Johns Hopkins University</nlm:aff><wicri:noCountry code="subfield">Johns Hopkins University</wicri:noCountry></affiliation></author><author><name sortKey="Tilley, Barbara" sort="Tilley, Barbara" uniqKey="Tilley B" first="Barbara" last="Tilley">Barbara Tilley</name><affiliation><nlm:aff id="A6"> University of Texas Health Science Center School of Public Health at Houston</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">20131372</idno><idno type="pmc">2891220</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2891220</idno><idno type="RBID">PMC:2891220</idno><idno type="doi">10.1002/mds.22997</idno><date when="2010">2010</date><idno type="wicri:Area/Pmc/Corpus">000190</idno><idno type="wicri:Area/Pmc/Curation">000190</idno><idno type="wicri:Area/Pmc/Checkpoint">000151</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Impact of belief in neuroprotection on therapeutic intervention in Parkinson disease</title><author><name sortKey="Elble, Rodger J" sort="Elble, Rodger J" uniqKey="Elble R" first="Rodger" last="Elble">Rodger Elble</name><affiliation><nlm:aff id="A1"> Department of Neurology, Southern Illinois University School of Medicine</nlm:aff><wicri:noCountry code="subfield">Southern Illinois University School of Medicine</wicri:noCountry></affiliation></author><author><name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name><affiliation><nlm:aff id="A2"> Departments of Medical Genetics and Clinical Neurosciences, University of Calgary</nlm:aff><wicri:noCountry code="subfield">University of Calgary</wicri:noCountry></affiliation></author><author><name sortKey="Shaftman, Stephanie" sort="Shaftman, Stephanie" uniqKey="Shaftman S" first="Stephanie" last="Shaftman">Stephanie Shaftman</name><affiliation><nlm:aff id="A3"> Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina</nlm:aff><wicri:noCountry code="subfield">Medical University of South Carolina</wicri:noCountry></affiliation></author><author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William" last="Weiner">William Weiner</name><affiliation><nlm:aff id="A4"> Department of Neurology, University of Maryland School of Medicine</nlm:aff><wicri:noCountry code="subfield">University of Maryland School of Medicine</wicri:noCountry></affiliation></author><author><name sortKey="Huang, Peng" sort="Huang, Peng" uniqKey="Huang P" first="Peng" last="Huang">Peng Huang</name><affiliation><nlm:aff id="A5"> Department of Oncology, Johns Hopkins University</nlm:aff><wicri:noCountry code="subfield">Johns Hopkins University</wicri:noCountry></affiliation></author><author><name sortKey="Tilley, Barbara" sort="Tilley, Barbara" uniqKey="Tilley B" first="Barbara" last="Tilley">Barbara Tilley</name><affiliation><nlm:aff id="A6"> University of Texas Health Science Center School of Public Health at Houston</nlm:aff></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><idno type="e-ISSN">1531-8257</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">We explored the hypotheses that an investigator’s belief in a putative neuroprotective agent might influence the timing of symptomatic intervention and the assessment of signs and symptoms of Parkinson patients with the Unified Parkinson Disease Rating Scale (UPDRS). These hypotheses were tested with Cox and general linear modeling, using data from a previously published double-blind placebo-controlled futility trial of coenzyme Q<sub>10</sub> and GPI-1485. We found the investigators’ level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment.</p></div></front></TEI><pmc article-type="research-article" xml:lang="EN"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">8610688</journal-id><journal-id journal-id-type="pubmed-jr-id">5937</journal-id><journal-id journal-id-type="nlm-ta">Mov Disord</journal-id><journal-title>Movement disorders : official journal of the Movement Disorder Society</journal-title><issn pub-type="ppub">0885-3185</issn><issn pub-type="epub">1531-8257</issn></journal-meta><article-meta><article-id pub-id-type="pmid">20131372</article-id><article-id pub-id-type="pmc">2891220</article-id><article-id pub-id-type="doi">10.1002/mds.22997</article-id><article-id pub-id-type="manuscript">NIHMS165374</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Impact of belief in neuroprotection on therapeutic intervention in Parkinson disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Elble</surname><given-names>Rodger J.</given-names></name><degrees>MD, PhD</degrees><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Suchowersky</surname><given-names>Oksana</given-names></name><degrees>MD</degrees><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Shaftman</surname><given-names>Stephanie</given-names></name><degrees>MSc, MS</degrees><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Weiner</surname><given-names>William J.</given-names></name><degrees>MD</degrees><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Peng</given-names></name><degrees>PhD</degrees><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Tilley</surname><given-names>Barbara</given-names></name><degrees>PhD</degrees><xref rid="A6" ref-type="aff">6</xref></contrib><on-behalf-of>on behalf of the NINDS NET-PD investigators</on-behalf-of></contrib-group><aff id="A1"><label>1</label> Department of Neurology, Southern Illinois University School of Medicine</aff><aff id="A2"><label>2</label> Departments of Medical Genetics and Clinical Neurosciences, University of Calgary</aff><aff id="A3"><label>3</label> Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina</aff><aff id="A4"><label>4</label> Department of Neurology, University of Maryland School of Medicine</aff><aff id="A5"><label>5</label> Department of Oncology, Johns Hopkins University</aff><aff id="A6"><label>6</label> University of Texas Health Science Center School of Public Health at Houston</aff><author-notes><corresp id="FN1">Correspondence: Dr. Elble, Rodger J. Elble, MD, PhD, Department of Neurology, Southern Illinois University School of Medicine, PO Box 19643, Springfield, IL 62794-9643, 217-545-7182 (phone), 217-545-1903 (Fax), <email>relble@siumed.edu</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>2</day><month>1</month><year>2010</year></pub-date><pub-date pub-type="ppub"><day>15</day><month>6</month><year>2010</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>6</month><year>2011</year></pub-date><volume>25</volume><issue>8</issue><fpage>1082</fpage><lpage>1086</lpage><abstract><p id="P1">We explored the hypotheses that an investigator’s belief in a putative neuroprotective agent might influence the timing of symptomatic intervention and the assessment of signs and symptoms of Parkinson patients with the Unified Parkinson Disease Rating Scale (UPDRS). These hypotheses were tested with Cox and general linear modeling, using data from a previously published double-blind placebo-controlled futility trial of coenzyme Q<sub>10</sub> and GPI-1485. We found the investigators’ level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment.</p></abstract><kwd-group><kwd>Parkinson disease</kwd><kwd>bias</kwd><kwd>clinical trial</kwd><kwd>Unified Parkinson Disease Rating Scale</kwd></kwd-group><contract-num rid="NS1">U01 NS043127-08
||NS</contract-num><contract-sponsor id="NS1">National Institute of Neurological Disorders and Stroke : NINDS</contract-sponsor></article-meta></front></pmc><affiliations><list></list><tree><noCountry><name sortKey="Elble, Rodger J" sort="Elble, Rodger J" uniqKey="Elble R" first="Rodger" last="Elble">Rodger Elble</name><name sortKey="Huang, Peng" sort="Huang, Peng" uniqKey="Huang P" first="Peng" last="Huang">Peng Huang</name><name sortKey="Shaftman, Stephanie" sort="Shaftman, Stephanie" uniqKey="Shaftman S" first="Stephanie" last="Shaftman">Stephanie Shaftman</name><name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name><name sortKey="Tilley, Barbara" sort="Tilley, Barbara" uniqKey="Tilley B" first="Barbara" last="Tilley">Barbara Tilley</name><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William" last="Weiner">William Weiner</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000151 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 000151 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= Pmc
|étape= Checkpoint
|type= RBID
|clé= PMC:2891220
|texte= Impact of belief in neuroprotection on therapeutic intervention in Parkinson disease
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i -Sk "pubmed:20131372" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a JankovicV1
| This area was generated with Dilib version V0.6.19. |  |